Please Wait
Applying Filters...
menu
    • menu
    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Camonsertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Repare's Lunresertib-Camonsertib Combo Shows Positive Ph 1 Results
    Repare's Lunresertib-Camonsertib Combo Shows Positive Ph 1 Results

    12 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241212081329/en

    BUSINESSWIRE
    12 Dec 2024
    Share Share
    Repare to Host Webcast on Lunresertib & Camonsertib Data
    Repare to Host Webcast on Lunresertib & Camonsertib Data

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210360746/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share
    Repare Therapeutics To Present Camonsertib Data At ESMO Congress 2024
    Repare Therapeutics To Present Camonsertib Data At ESMO Congress 2024

    13 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913906467/en

    BUSINESSWIRE
    13 Sep 2024
    Share Share
    Repare Doses First Patient In Camonsertib Non-Small Cell Lung Cancer Trial
    Repare Doses First Patient In Camonsertib Non-Small Cell Lung Cancer Trial

    10 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240610868857/en

    BUSINESSWIRE
    10 Jun 2024
    Share Share
    Repare Therapeutics: FDA Granted Fast Track For Lunresertib+Camonsertib
    Repare Therapeutics: FDA Granted Fast Track For Lunresertib+Camonsertib

    04 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240604315065/en

    BUSINESSWIRE
    04 Jun 2024
    Share Share